WallStreetZenWallStreetZen

NASDAQ: VYGR
Voyager Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Voyager Therapeutics revenue was $80.00M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $6.3M, down 74.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, VYGR annual revenue was $80.0M, with -68% growth year-over-year.

VYGR past revenue growth

How has VYGR's revenue growth performed historically?

Company
-68%
Industry
437.31%
Market
20.27%
VYGR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VYGR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VYGR's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VYGR revenue history

Current Revenue
$80.0M
Current Earnings
-$65.0M
Current Profit Margin
-81.3%

Be the first to know when VYGR announces revenue.

VYGR Revenue History By Year

VYGR Yearly RevenueVYGR RevenueVYGR ChangeVYGR Revenue Growth
2024-12-31$80.00M-$170.01M-68.00%
2023-12-31$250.01M$209.10M+511.16%
2022-12-31$40.91M$3.49M+9.33%
2021-12-31$37.42M-$133.71M-78.14%
2020-12-31$171.13M$66.74M+63.93%
2019-12-31$104.39M$96.77M+1,270.14%
2018-12-31$7.62M-$2.52M-24.82%
2017-12-31$10.14M-$4.09M-28.73%
2016-12-31$14.22M-$3.11M-17.96%
2015-12-31$17.33MN/AN/A
2014-12-31$0.00N/AN/A

1 of 1

Voyager Therapeutics Revenue FAQ

What was VYGR's revenue last quarter?

On Invalid Date, Voyager Therapeutics (NASDAQ: VYGR) reported Q4 2024 revenue of $6.28 million up 93.03% year over year. In the same quarter last year, Voyager Therapeutics's revenue was $90.06 million.

What was Voyager Therapeutics's revenue in 2024?

Voyager Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $80.00 million, a 68% decrease year over year.

How much does Voyager Therapeutics make in a day?

Based on Voyager Therapeutics annual revenue for the past five years, VYGR makes an average of $317,511.78 per day.

What was Voyager Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Voyager Therapeutics's revenue has grown -68% year over year. This is 505.31 percentage points lower than the US Biotechnology industry revenue growth rate of 437.31%. Voyager Therapeutics's revenue in the past year totaled $80.00 million.

How much does Voyager Therapeutics make in a year?

Voyager Therapeutics's revenue by year for the past five years is:
  • Voyager Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $80.00 million, a 68% decrease year over year.
  • Voyager Therapeutics's annual revenue for Dec 31, 2023 was $250.01 million, a 511.16% increase from 2022.
  • Voyager Therapeutics's annual revenue for 2022 was $40.91 million, a 9.33% increase from 2021.
  • Voyager Therapeutics's annual revenue for 2021 was $37.42 million, a 78.14% decrease from 2020.
  • Voyager Therapeutics's annual revenue for 2020 was $171.13 million, a 63.93% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.